S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$21.52
+0.08 (+0.37%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.00
$21.74
50-Day Range
$17.57
$22.27
52-Week Range
$15.50
$23.40
Volume
2.55 million shs
Average Volume
1.83 million shs
Market Capitalization
$6.90 billion
P/E Ratio
23.39
Dividend Yield
N/A
Price Target
$31.13

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
44.6% Upside
$31.13 Price Target
Short Interest
Healthy
3.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
-0.29mentions of Exelixis in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.13 M Sold Last Quarter
Proj. Earnings Growth
26.60%
From $0.94 to $1.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.24 out of 5 stars

Medical Sector

7th out of 1,283 stocks

Biological Products, Except Diagnostic Industry

1st out of 197 stocks

EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis Stock Up 0.4 %

EXEL Stock opened at $21.52 on Friday. Exelixis has a 12-month low of $15.50 and a 12-month high of $23.40. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 23.39, a PEG ratio of 0.63 and a beta of 0.60. The company has a 50 day moving average of $20.39 and a two-hundred day moving average of $20.48.

Exelixis (NASDAQ:EXEL - Get Rating) last released its earnings results on Tuesday, May 10th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.07. The company had revenue of $356.00 million during the quarter, compared to the consensus estimate of $363.22 million. Exelixis had a net margin of 19.60% and a return on equity of 13.77%. The company's revenue was up 31.7% on a year-over-year basis. On average, research analysts anticipate that Exelixis will post 0.94 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on EXEL shares. Piper Sandler raised their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock an "overweight" rating in a report on Tuesday, July 26th. Jefferies Financial Group began coverage on shares of Exelixis in a research note on Thursday, May 12th. They issued a "buy" rating and a $28.00 price objective for the company. BMO Capital Markets began coverage on shares of Exelixis in a research note on Thursday, June 23rd. They issued an "outperform" rating and a $28.00 price objective for the company. StockNews.com lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 18th. Finally, Morgan Stanley raised their price objective on shares of Exelixis from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Friday, July 15th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.13.

Insider Activity

In other news, EVP Patrick J. Haley sold 18,812 shares of the firm's stock in a transaction on Friday, May 27th. The shares were sold at an average price of $18.21, for a total transaction of $342,566.52. Following the transaction, the executive vice president now owns 239,818 shares in the company, valued at approximately $4,367,085.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Lance Willsey sold 40,000 shares of Exelixis stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $19.65, for a total value of $786,000.00. Following the transaction, the director now owns 424,415 shares in the company, valued at approximately $8,339,754.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 18,812 shares of Exelixis stock in a transaction on Friday, May 27th. The stock was sold at an average price of $18.21, for a total transaction of $342,566.52. Following the completion of the transaction, the executive vice president now owns 239,818 shares in the company, valued at approximately $4,367,085.78. The disclosure for this sale can be found here. 2.90% of the stock is owned by insiders.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Analysts Set Exelixis, Inc. (NASDAQ:EXEL) PT at $31.13
Exelixis (NASDAQ:EXEL) PT Raised to $32.00
1 Reason to Buy Exelixis Stock, and 1 Reason to Sell
Analyzing Immunocore (NASDAQ:IMCR) and Exelixis (NASDAQ:EXEL)
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
5/10/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
954
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$31.13
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+44.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$231.06 million
Pretax Margin
25.08%

Debt

Sales & Book Value

Annual Sales
$1.43 billion
Cash Flow
$0.77 per share
Book Value
$6.99 per share

Miscellaneous

Free Float
311,440,000
Market Cap
$6.90 billion
Optionable
Optionable
Beta
0.60

Social Links















EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis
or view top-rated stocks.

What is Exelixis' stock price forecast for 2022?

8 equities research analysts have issued 1-year price objectives for Exelixis' shares. Their EXEL stock forecasts range from $23.00 to $42.00. On average, they predict Exelixis' stock price to reach $31.13 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price.
View analysts' price targets for Exelixis
or view top-rated stocks among Wall Street analysts.

How has Exelixis' stock performed in 2022?

Exelixis' stock was trading at $18.28 at the beginning of the year. Since then, EXEL shares have increased by 17.7% and is now trading at $21.52.
View the best growth stocks for 2022 here
.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Exelixis
.

How can I listen to Exelixis' earnings call?

Exelixis will be holding an earnings conference call on Tuesday, August 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "8698613".

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Tuesday, May, 10th. The biotechnology company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.07. The biotechnology company had revenue of $356 million for the quarter, compared to analyst estimates of $363.22 million. Exelixis had a trailing twelve-month return on equity of 13.77% and a net margin of 19.60%. The business's revenue was up 31.7% on a year-over-year basis.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.63 billion, compared to the consensus revenue estimate of $1.64 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Meditor Group Ltd (2.41%), Stephens Investment Management Group LLC (1.26%), Candriam S.C.A. (0.59%), Assenagon Asset Management S.A. (0.58%), Scout Investments Inc. (0.45%) and Allspring Global Investments Holdings LLC (0.35%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $21.52.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.90 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.92 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 954 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for Exelixis is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.